Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
A.AlharbiM.MekkyA
However, dermatologists emphasize that results depend on consistency, genetics, and medical supervision
A novel and simple approach for extraction and isolation of curcuminoids from turmeric rhizomes
Our knowledgeable, compassionate team of expert nurse injectors, wellness advisors, and skincare specialists are here to answer any questions and guide you through the process
Studies on animals show that selenomethionine keeps blood selenium levels higher when intake drops [17]